Sophie C. Siegmund

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Comparative assessment of KDIGO and CTCAE criteria for detecting renal function deterioration after peptide receptor radionuclide therapy.

Comparative assessment of KDIGO and CTCAE criteria for detecting renal function deterioration after peptide receptor radionuclide therapy.

Journal: European journal of nuclear medicine and molecular imaging
Published: June 24, 2026

Recent advances in PSMA therapy - from beta to alpha.

Recent advances in PSMA therapy - from beta to alpha.

Journal: Annals of nuclear medicine
Published: June 12, 2026

Fibroblast Activation Protein: Molecular Imaging and Beyond.

Fibroblast Activation Protein: Molecular Imaging and Beyond.

Journal: PET clinics
Published: April 30, 2026

Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry.

Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry.

Journal: European journal of nuclear medicine and molecular imaging
Published: April 29, 2026

Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck.

Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck.

Journal: Nuklearmedizin. Nuclear medicine
Published: February 25, 2026

[177Lu]Lu-PSMA radioligand therapy in younger prostate cancer patients: A matched-pair analysis between patients ≤ 65 and ≥ 70 years old.

[177Lu]Lu-PSMA radioligand therapy in younger prostate cancer patients: A matched-pair analysis between patients ≤ 65 and ≥ 70 years old.

Journal: European journal of nuclear medicine and molecular imaging
Published: December 22, 2025

Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [177Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA Dynamics.

Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [177Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA Dynamics.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 08, 2025

Investigation of iterative deconvolution in 177Lu-SPECT imaging for lesion dosimetry.

Investigation of iterative deconvolution in 177Lu-SPECT imaging for lesion dosimetry.

Journal: EJNMMI physics
Published: November 26, 2025

Estimation of split renal function on PET using the SSTR-targeting radioligands [18F]SiTATE, [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-TOC in a theranostic setting.

Estimation of split renal function on PET using the SSTR-targeting radioligands [18F]SiTATE, [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-TOC in a theranostic setting.

Journal: European journal of nuclear medicine and molecular imaging
Published: November 26, 2025

Current status of FAP therapy in solid tumors.

Current status of FAP therapy in solid tumors.

Journal: Seminars in nuclear medicine
Published: November 20, 2025

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results.

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results.

Journal: European journal of nuclear medicine and molecular imaging
Published: November 17, 2025

Options in nuclear medicine for advanced prostate cancer in practice

Options in nuclear medicine for advanced prostate cancer in practice

Journal: Radiologie (Heidelberg, Germany)
Published: October 20, 2025
Showing 1-12 of 25

Last Updated: 09/26/2026